Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Research Report- Forecast to 2030

Middle East and Africa Urinary Tract Infection (UTI) Drugs Market Research Report Information by Drug Class (Quinolones, Aminoglycosides, β-lactam, Azoles and others), Clinical Indications (Urethritis, Cystitis, Pyelonephritis) and End User (Hospitals and Self-administered) - Forecast to 2030

ID: MRFR/Pharma/1900-HCR | 84 Pages | Author: Kinjoll Dey | November 2023         

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure:

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces Model

4.1.1 Bargaining Power of Suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Middle East and Africa UTI Drugs Market, by Drug Class

5.1 Introduction

5.1.1 Quinolones

5.1.2 Aminoglycosides

5.1.3 β-lactam

5.1.4 Azoles

5.1.5 Others

6 Middle East and Africa UTI Drugs Market, by Clinical Indications

6.1 Introduction

6.1.1 Urethritis

6.1.2 Cystitis

6.1.3 Pyelonephritis

7 Middle East and Africa UTI Drugs Market, by End User

7.1 Introduction

7.1.1 Hospitals

7.1.3 Self-administered

8 Middle East and Africa UTI Drugs Market, by Country

8.1 Introduction

8.2 UAE

8.3 Egypt

8.4 Saudi Arabia

8.5 Kuwait

8.6 Qatar

8.7 Oman

9 Company Landscape

9.1 Introduction

9.1.1 Mergers Acquisitions

9.1.2 Collaborations

9.1.3 Release/New Product Launches

9.1.4 Other (Expansion, Updates, Partnership)

10 Company Profile

10.1 Bayer AG

10.1.1 Company Overview

10.1.2 Product/Business Segment Overview

10.1.3 Financials

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Novartis AG

10.2.1 Overview

10.2.2 Product/Business Segment Overview

10.2.3 Financials

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Pfizer Inc.

10.3.1 Overview

10.3.2 Product/Business Segment Overview

10.3.3 Financials

10.3.4 Key Developments

10.3.5 SWOT Analysis

10.4 F. Hoffmann-La Roche Ltd

10.4.1 Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financials

10.4.4 Key Developments

10.4.5 SWOT Analysis

10.5 AstraZeneca

10.5.1 Overview

10.5.2 Product/Business Segment Overview

10.5.3 Financials

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Cipla Inc.

10.6.1 Overview

10.6.2 Product/Business Segment Overview

10.6.3 Financials

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Dr. Reddy’s Laboratories Ltd

10.7.1 Overview

10.7.2 Product/Business Segment Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Others

11 Appendix

List of Tables

TABLE 1 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS, 2020-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY DRUG CLASS

FIGURE 4 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY CLINICAL INDICATIONS

FIGURE 5 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY END USER

FIGURE 6 MIDDLE EAST AND AFRICA UTI DRUGS MARKET, BY REGION

FIGURE 7 MIDDLE EAST AND AFRICA UTI DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid